Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.
Fiche publication
Date publication
février 2021
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent, Dr BERTAUT Aurélie, Dr COUDERT Bruno, Pr COUTANT Charles, Pr GHIRINGHELLI François, Dr LADOIRE Sylvain, Mme TRUNTZER Caroline, Dr VINCENT Julie, Dr HERVIEU Alice, Dr FAVIER Laure, Dr BENGRINE-LEFEVRE Leila, Dr DESMOULINS Isabelle, Dr FUMET Jean-David, Dr HENNEQUIN Audrey, Dr ZANETTA Sylvie, Dr MAYEUR Didier
Tous les auteurs :
Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hanu R, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F
Lien Pubmed
Résumé
In view of the potential gravity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and patients with cancer at a large cancer centre, at the end of the period of first national lockdown in France and to determine factors associated with the risk of SARS-CoV-2 infection.
Mots clés
Antibody, COVID-19, Cancer center, Cancer patients, Healthcare workers, SARS-COV-2, Serodiagnosis, Serology, Seroprevalence, Staff
Référence
Eur J Cancer. 2021 Feb 27;148:359-370